MedTrace Logo

Safety Evaluation of THC-Free Hemp Protein Isolate

NCT07022275 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-12

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are:

Does twice-daily consumption of 20 grams of Agoge Hemp Protein Powder for 30 days result in detectable levels of THC-COOH, the primary metabolite of THC, in urine samples? Is the supplement well tolerated, and does it affect common clinical safety markers (e.g., liver and kidney function, inflammatory markers)?

This is a single-arm study with no comparison group. All participants will:

* Consume 20 grams of the hemp protein supplement twice daily for 30 days
* Provide blood and urine samples at baseline and Day 30
* Complete weekly surveys assessing adherence, tolerability, and adverse events

Conditions

  • Tolerability of Hemp Protein

Interventions

DIETARY_SUPPLEMENT

Hemp protein powder

Agoge Universal Hemp Protein Powder - A certified cannabinoid-free hemp protein powder.

Sponsors & Collaborators

  • National University of Natural Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-15
Primary Completion
2026-04-25
Completion
2026-04-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07022275 on ClinicalTrials.gov